Please provide your email address to receive an email when new articles are posted on . Change in HbA1c and hypoglycemia rates were similar between once-weekly basal insulin and once-daily insulin ...

Dexcom Smart Basal is designed to make basal insulin initiation and management simpler and more personalized for users and their healthcare providers. * Dexcom Smart Basal is FDA cleared and now the ...

Bagsværd, Denmark, 21 March 2024 – Novo Nordisk today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion, recommending ...

Insulin icodec-abae (Awiqli; Novo Nordisk) is now approved for use in the US, Canada, European Union, Switzerland, and 12 other countries. Its indication is as an adjunct to diet and exercise for ...

The overall safety of insulin efsitora was similar to that of daily basal insulin therapies. Topline data were announced from 2 studies in the QWINT phase 3 clinical development program investigating ...

Data from the ONWARDS clinical trial program supported the efficacy of once-weekly insulin icodec-abae compared with daily basal insulin. The Food and Drug Administration (FDA) has approved Awiqli ® ...

SAN DIEGO – The investigational once-weekly insulin icodec provided superior glucose control compared with the once-daily basal insulins degludec and glargine in type 2 diabetes, results from two new ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Once-weekly insulin efsitora alfa was noninferior to ...

Medical device software company Voluntis has received an updated FDA clearance (as well as an updated CE mark) for its Insulia app, a "digital companion" app for people with Type 2 diabetes. Insulia ...

The FDA has approved Novo Nordisk’s Awiqli (insulin icodec-abae), making it the first once-weekly basal insulin available in the U.S. for adults with Type 2 diabetes. Awiqli is indicated as an adjunct ...

Add Yahoo as a preferred source to see more of our stories on Google. The clinical trials assessed once-weekly Awiqli with mealtime insulin Novo Nordisk has secured the US Food and Drug Administration ...

Conclusions: Compared with patients with no hypoglycemia-related claims in year 1 after basal insulin initiation, patients with a hypoglycemia-related claim had a greater burden of complications and ...